Comment on CMS-2026-1256-0002

Summary: Genetix Biotherapeutics, a biotechnology company, supports the proposed action but argues that the current MS-DRG system is inadequate for high-cost, low-volume ex vivo gene therapies. They recommend creating a dedicated MS-DRG for these therapies or, alternatively, implementing a targeted high-cost, low-volume drug adjustment to ensure hospitals are reimbursed for the significant costs of these treatments.